Enantiospecific inhibition of ligature-induced periodontitis in beagles with topical (S)-ketoprofen.
Systemic and topical administration of non-steroidal anti-inflammatory drugs (NSAIDs) has been shown to reduce periodontal disease progression in both animal models and human subjects. Our present research focuses on single enantiomers of these agents to examine whether enantiospecific therapy will be efficacious in slowing periodontitis. The purpose of this study was to evaluate the inhibitory effects of (S)-ketoprofen on experimentally induced alveolar bone loss in beagle dogs. 16, 18-month-old, female beagles were brought to optimal periodontal health over a 2-week pretreatment period. Experimental periodontitis was then induced by placing silk ligatures around premolar and molar teeth and by instituting a soft, plaque-promoting diet. At baseline, animals were randomized to 1 of 4 groups, consisting of 2x daily administration of (1) placebo dentifrice, (2) 0.3% (S)-ketoprofen dentifrice, (3) 3.0% (S)-ketoprofen dentifrice, or (4) 10.0 mg (S)-ketoprofen capsules (p.o.) over a 60 day treatment period. Standardized, periapical radiographs exposed at days 1 and 60 were analyzed by computer-assisted digital radiography in order to assess the rate of alveolar bone loss. Secondary outcomes included technetium 99m-tin-diphosphonate (99mTc-Sn-MDP) uptake and the gingival index. At baseline, no differences were observed among the groups for linear bone height or 99mTc-Sn-MDP uptake ratios. From days 1 to 60, cohorts differed significantly in terms of bone loss rates (p < 0.001). In particular, beagles treated with systemic or topical (S)-ketoprofen (0.3% or 3.0% dentifrices) exhibited significantly lower mean rates of bone loss compared to placebo treated beagles (p < 0.05). Group differences in mean radiopharmaceutical uptake ratio changes approached significance (ANOVA, p = 0.07), where animals treated with topical 0.3% (S)-ketoprofen demonstrated a reduction and other groups demonstrated elevations over the 60-day dosing period. Treatment cohorts did differ significantly with respect to changes in mean gingival indices (p < 0.05). Animals treated with 0.3% or 3.0% (S)-ketoprofen dentifrice exhibited significantly reduced elevations in gingival index scores as compared to placebo treated animals. These data provide evidence that enantiospecific therapy with (S)-ketoprofen, topically or systemically delivered, may alter the progression of periodontal disease in the beagle dog model.
Paquette
D W
DW
Department of Periodontics, University of North Carolina School of Dentistry, Chapel Hill, USA. David_Paquette@dentistry.unc.edu
Fiorellini
J P
JP
Martuscelli
G
G
Oringer
R J
RJ
Howell
T H
TH
McCullough
J R
JR
Reasner
D S
DS
Williams
R C
RC
D016301:Alveolar Bone Loss / Q000000981:diagnostic imaging / Q000517:prevention & control*; D000704:Analysis of Variance; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D002214:Capsules; D015331:Cohort Studies; D003802:Dentifrices / Q000627:therapeutic use; D004195:Disease Models, Animal; D018450:Disease Progression; D004285:Dogs; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007660:Ketoprofen / Q000008:administration & dosage / Q000627:therapeutic use*; D008026:Ligation; D010486:Periapical Tissue / Q000000981:diagnostic imaging; D010512:Periodontal Index; D010518:Periodontitis / Q000000981:diagnostic imaging / Q000517:prevention & control*; D010919:Placebos; D011856:Radiographic Image Enhancement; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D011897:Random Allocation; D013237:Stereoisomerism; D013669:Technetium Tc 99m Medronate; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002214:Capsules; D003802:Dentifrices; D010919:Placebos; D019275:Radiopharmaceuticals; C023568:technetium Tc 99m (Sn)methylenediphosphonate; D007660:Ketoprofen; D013669:Technetium Tc 99m Medronate